Compare RDW & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | PCRX |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | RDW | PCRX |
|---|---|---|
| Price | $8.22 | $25.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $12.67 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 10.8M | 916.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $296,147,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $11.62 | $6.24 |
| Revenue Next Year | $42.89 | $9.53 |
| P/E Ratio | ★ N/A | $55.21 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $4.87 | $18.17 |
| 52 Week High | $26.66 | $27.64 |
| Indicator | RDW | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 56.92 |
| Support Level | $6.32 | $25.48 |
| Resistance Level | $8.20 | $27.16 |
| Average True Range (ATR) | 0.79 | 1.00 |
| MACD | 0.24 | 0.03 |
| Stochastic Oscillator | 77.47 | 56.64 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.